Clinical Trials Logo
  1. Home
  2. Urinary Bladder Neoplasm
  3. NCT04144270

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Urinary Bladder Neoplasm Clinical Trial

Official title:
The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Clinical Trial Summary

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04144270
Study type Observational
Source Rigshospitalet, Denmark
Contact Lise Hoej Omland, MD
Phone +45 35450782
Email lise.hoej.omland@regionh.dk
Status Recruiting
Phase
Start date November 18, 2019
Completion date April 2021
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05429710 - SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Not yet recruiting NCT05097105 - Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses
Completed NCT02966535 - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial N/A
Completed NCT02977143 - Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery N/A
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Recruiting NCT06238479 - A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Phase 1
Completed NCT02311101 - Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer Phase 1
Recruiting NCT04811846 - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood N/A
Recruiting NCT04576286 - Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder Phase 3
Completed NCT02857634 - Confocal Microscopy Dual Band in the Management of Bladder Cancer
Recruiting NCT04561362 - Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Phase 1/Phase 2
Recruiting NCT04442724 - Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy N/A
Recruiting NCT04029948 - Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours N/A
Terminated NCT03389438 - Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Phase 2
Terminated NCT02952989 - A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06237920 - Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab Phase 2
Completed NCT03785925 - A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Phase 2
Completed NCT03636256 - Evaluation of NanoDoce® in Participants With Urothelial Carcinoma Phase 1/Phase 2